NEW YORK (GenomeWeb) – DermTech announced today that it has been accredited by the New York State Department of Health to provide laboratory services in the state.
As a result, DermTech can provide such services in all 50 states in the US and the District of Columbia. The company operates a CLIA-certified laboratory at its La Jolla, California-based headquarter.
"Receiving this accreditation is a critical achievement, enabling us to provide molecular pathology services to dermatologists and dermapathologists across the country," DermTech CEO John Dobak said in a statement.
Last month, the company said that its licensee DermTech Canada received approval to market the company's pigmented lesions assay and noninvasive biopsy kit for melanoma detection in Canada. In November, the firm raised $10 million in a preferred equity offering.